vs
Ardmore Shipping Corp(ASC)与Health Catalyst, Inc.(HCAT)财务数据对比。点击上方公司名可切换其他公司
Ardmore Shipping Corp的季度营收约是Health Catalyst, Inc.的1.1倍($81.2M vs $74.7M),Ardmore Shipping Corp净利率更高(15.7% vs -121.9%,领先137.6%),Health Catalyst, Inc.同比增速更快(-6.2% vs -15.5%),过去两年Health Catalyst, Inc.的营收复合增速更高(-0.0% vs -6.0%)
阿德莫尔航运是一家全球化海上运输企业,持有并运营中型成品油轮与化学品运输船队,可为全球能源、化工及贸易领域客户提供石油产品、特种化学品及其他散装液态货物的海运服务。
Catalyst制药公司是一家总部位于美国佛罗里达州科勒尔盖布尔斯的生物制药企业,专注于开发罕见病治疗药物。其开发的阿米夫斯汀磷酸盐商品名为Firdapse,原本已获FDA批准用于成人兰伯特-伊顿肌无力综合征(LEMS)的治疗,2018年11月又获批可用于6岁及以上儿童LEMS患者。
ASC vs HCAT — 直观对比
营收规模更大
ASC
是对方的1.1倍
$74.7M
营收增速更快
HCAT
高出9.3%
-15.5%
净利率更高
ASC
高出137.6%
-121.9%
两年增速更快
HCAT
近两年复合增速
-6.0%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | ||
|---|---|---|
| 营收 | $81.2M | $74.7M |
| 净利润 | $12.8M | $-91.0M |
| 毛利率 | — | — |
| 营业利润率 | 16.1% | -115.3% |
| 净利率 | 15.7% | -121.9% |
| 营收同比 | -15.5% | -6.2% |
| 净利润同比 | -47.0% | -340.3% |
| 每股收益(稀释后) | $0.30 | $-1.29 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比,按日历期对齐,财年错位的公司也能正确匹配
营收
ASC
HCAT
| Q4 25 | — | $74.7M | ||
| Q3 25 | $81.2M | $76.3M | ||
| Q2 25 | $72.0M | $80.7M | ||
| Q1 25 | $74.0M | $79.4M | ||
| Q4 24 | — | $79.6M | ||
| Q3 24 | $96.1M | $76.4M | ||
| Q2 24 | $121.3M | $75.9M | ||
| Q1 24 | $106.3M | $74.7M |
净利润
ASC
HCAT
| Q4 25 | — | $-91.0M | ||
| Q3 25 | $12.8M | $-22.2M | ||
| Q2 25 | $9.6M | $-41.0M | ||
| Q1 25 | $6.3M | $-23.7M | ||
| Q4 24 | — | $-20.7M | ||
| Q3 24 | $24.1M | $-14.7M | ||
| Q2 24 | $62.7M | $-13.5M | ||
| Q1 24 | $39.2M | $-20.6M |
毛利率
ASC
HCAT
| Q4 25 | — | — | ||
| Q3 25 | — | 52.6% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 47.5% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
营业利润率
ASC
HCAT
| Q4 25 | — | -115.3% | ||
| Q3 25 | 16.1% | -22.9% | ||
| Q2 25 | 13.5% | -46.0% | ||
| Q1 25 | 8.6% | -25.4% | ||
| Q4 24 | — | -22.0% | ||
| Q3 24 | 25.4% | -17.9% | ||
| Q2 24 | 51.3% | -20.8% | ||
| Q1 24 | 37.2% | -30.5% |
净利率
ASC
HCAT
| Q4 25 | — | -121.9% | ||
| Q3 25 | 15.7% | -29.1% | ||
| Q2 25 | 13.3% | -50.8% | ||
| Q1 25 | 8.5% | -29.9% | ||
| Q4 24 | — | -26.0% | ||
| Q3 24 | 25.1% | -19.3% | ||
| Q2 24 | 51.7% | -17.8% | ||
| Q1 24 | 36.9% | -27.6% |
每股收益(稀释后)
ASC
HCAT
| Q4 25 | — | $-1.29 | ||
| Q3 25 | $0.30 | $-0.32 | ||
| Q2 25 | $0.22 | $-0.59 | ||
| Q1 25 | $0.14 | $-0.35 | ||
| Q4 24 | — | $-0.33 | ||
| Q3 24 | $0.55 | $-0.24 | ||
| Q2 24 | $1.47 | $-0.23 | ||
| Q1 24 | $0.92 | $-0.35 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | ||
|---|---|---|
| 现金及短期投资手头流动性 | — | $95.7M |
| 总债务越低越好 | $116.1M | $153.3M |
| 股东权益账面价值 | $628.2M | $245.8M |
| 总资产 | $799.8M | $502.6M |
| 负债/权益比越低杠杆越低 | 0.18× | 0.62× |
8季度趋势,按日历期对齐
现金及短期投资
ASC
HCAT
| Q4 25 | — | $95.7M | ||
| Q3 25 | — | $91.5M | ||
| Q2 25 | — | $97.3M | ||
| Q1 25 | — | $342.0M | ||
| Q4 24 | — | $392.0M | ||
| Q3 24 | — | $387.3M | ||
| Q2 24 | — | $308.3M | ||
| Q1 24 | — | $327.8M |
总债务
ASC
HCAT
| Q4 25 | — | $153.3M | ||
| Q3 25 | $116.1M | $153.1M | ||
| Q2 25 | $25.0M | $153.0M | ||
| Q1 25 | $20.5M | $382.9M | ||
| Q4 24 | — | $382.4M | ||
| Q3 24 | $22.5M | $345.0M | ||
| Q2 24 | $44.2M | — | ||
| Q1 24 | $23.1M | — |
股东权益
ASC
HCAT
| Q4 25 | — | $245.8M | ||
| Q3 25 | $628.2M | $331.9M | ||
| Q2 25 | $618.3M | $347.5M | ||
| Q1 25 | $610.7M | $376.8M | ||
| Q4 24 | — | $365.2M | ||
| Q3 24 | $627.0M | $355.0M | ||
| Q2 24 | $617.7M | $357.0M | ||
| Q1 24 | $567.9M | $357.2M |
总资产
ASC
HCAT
| Q4 25 | — | $502.6M | ||
| Q3 25 | $799.8M | $587.1M | ||
| Q2 25 | $703.8M | $616.2M | ||
| Q1 25 | $690.4M | $891.5M | ||
| Q4 24 | — | $858.9M | ||
| Q3 24 | $722.8M | $813.0M | ||
| Q2 24 | $742.0M | $691.7M | ||
| Q1 24 | $704.1M | $695.1M |
负债/权益比
ASC
HCAT
| Q4 25 | — | 0.62× | ||
| Q3 25 | 0.18× | 0.46× | ||
| Q2 25 | 0.04× | 0.44× | ||
| Q1 25 | 0.03× | 1.02× | ||
| Q4 24 | — | 1.05× | ||
| Q3 24 | 0.04× | 0.97× | ||
| Q2 24 | 0.07× | — | ||
| Q1 24 | 0.04× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | ||
|---|---|---|
| 经营现金流最新季度 | $17.9M | $9.9M |
| 自由现金流经营现金流 - 资本支出 | — | $9.6M |
| 自由现金流率自由现金流/营收 | — | 12.9% |
| 资本支出强度资本支出/营收 | — | 0.4% |
| 现金转化率经营现金流/净利润 | 1.40× | — |
| 过去12个月自由现金流最近4个季度 | — | $-697.0K |
8季度趋势,按日历期对齐
经营现金流
ASC
HCAT
| Q4 25 | — | $9.9M | ||
| Q3 25 | $17.9M | $-464.0K | ||
| Q2 25 | $11.2M | $-9.0M | ||
| Q1 25 | $26.3M | $280.0K | ||
| Q4 24 | — | $-3.5M | ||
| Q3 24 | $39.9M | $6.2M | ||
| Q2 24 | $48.4M | $1.6M | ||
| Q1 24 | $49.2M | $10.3M |
自由现金流
ASC
HCAT
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $-719.0K | ||
| Q2 25 | — | $-9.2M | ||
| Q1 25 | — | $-390.0K | ||
| Q4 24 | — | $-3.9M | ||
| Q3 24 | — | $5.5M | ||
| Q2 24 | — | $1.3M | ||
| Q1 24 | — | $10.1M |
自由现金流率
ASC
HCAT
| Q4 25 | — | 12.9% | ||
| Q3 25 | — | -0.9% | ||
| Q2 25 | — | -11.4% | ||
| Q1 25 | — | -0.5% | ||
| Q4 24 | — | -4.9% | ||
| Q3 24 | — | 7.2% | ||
| Q2 24 | — | 1.7% | ||
| Q1 24 | — | 13.5% |
资本支出强度
ASC
HCAT
| Q4 25 | — | 0.4% | ||
| Q3 25 | — | 0.3% | ||
| Q2 25 | — | 0.3% | ||
| Q1 25 | — | 0.8% | ||
| Q4 24 | — | 0.5% | ||
| Q3 24 | — | 0.9% | ||
| Q2 24 | — | 0.4% | ||
| Q1 24 | — | 0.3% |
现金转化率
ASC
HCAT
| Q4 25 | — | — | ||
| Q3 25 | 1.40× | — | ||
| Q2 25 | 1.17× | — | ||
| Q1 25 | 4.20× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.65× | — | ||
| Q2 24 | 0.77× | — | ||
| Q1 24 | 1.25× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASC
暂无分部数据
HCAT
| Recurring Technology | $51.9M | 69% |
| Professional Services | $22.8M | 31% |